Experience With Apomorphine On-Demand Therapy in PD
PD OFF Episodes: Optimizing Use of On-Demand Therapy
Altering Oral PD Regimens Versus Using On-Demand Therapy
Gastroparesis and Uptake of Oral Medication for Parkinson Disease
Educating Patients on Signs of Parkinson Disease OFF Episodes
Different Types of OFF Episodes in Parkinson Disease
Inhalation Powder for Off Episodes of Parkinson Disease
Shifting the Paradigm to On-Demand Therapies in PD
Improving QoL in Patients with Parkinson Disease
Differentiating Off Episodes in Parkinson Disease
Off Episodes in a 63-Year-Old Woman With Parkinson
Reviewing a Case of Parkinson Disease OFF Episodes
CMSC 2020 Day 1: Patricia Melville, Marijean Buhse, PhD, on Comorbidities and Critical Thinking About DMTs and Vaccines
Patricia Melville, NP-C, MSCN, and Marijean Buhse, PhD, NP-C, MSCN, present their lecture titled, "Comorbidities and MS: Critical Thinking About DMTs and Vaccines" as part of the 2020 CMSC Virtual Annual Meeting.
CMSC 2020 Day 1: Peter Calabresi, MD, on CNS Immune Responses in Progressive MS
Peter Calabresi, MD, delivers the Whitaker Lecture as part of the 2020 CMSC Virtual Annual Meeting.
CMSC 2020 Day 1: Amy Sullivan, PsyD, ABPP, on Science, Art, and Practice of Behavioral Medicine in MS
Amy Sullivan, PsyD, ABPP, presents her lecture titled, "Science, Art, and Practice of Behavioral Medicine" as part of the 2020 CMSC Virtual Annual Meeting.
CMSC 2020 Day 1: Brian Weinshenker, MD, on Emerging Treatment Options for NMOSD
Brian Weinshenker, MD presents his lecture titled, "Neuromyelitis Optica Spectrum Disorders: Emerging Treatment Options" as part of the 2020 CMSC Virtual Annual Meeting.
CMSC 2020 Day 1: Patricia Coyle, MD on Diagnosis, Clinical Course, and Long-Term Management of Progressive MS
Patricia Coyle, MD, delivers her lecture titled, "Progressive MS: Diagnosis, Clinical Course and Long-Term Management" as part of the 2020 CMSC Virtual Annual Meeting.
Evobrutinib Shows Long-Term Efficacy and Safety in Phase 2 Study
Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.
Optimizing Outcomes for Patients With MS
Ofatumumab for Relapsing MS
Treating Relapsing MS With Ocrelizumab
Ocrelizumab for Relapsing MS
Response to Cladribine Tablets in RRMS
Repository Corticotropin Injection for RRMS
Relapse Recovery and Outcomes in MS
Repository Corticotropin Injection for Relapsing MS
The Gut Microbiota and Risk of Relapse in MS
Goals of Therapy for Relapsing MS
Escalation Versus Induction Therapy in Relapsing Multiple Sclerosis
Ocrelizumab Has Similar Effects in MS With Shorter Infusion Time
The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.
